Adaptimmune Quarterly report pursuant to Section 13 or 15(d)

Accrued expenses and other current liabilities

3 Months Ended

Mar. 31, 2021

Note 9 — Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	March 31,		December 31,
	2021		2020
Accrued clinical and development expenditure	$	13,577	$	13,081
Accrued employee expenses		5,836		11,825
Other accrued expenditure		2,459		2,126
Other		391		47
	$	22,263	$	27,079